Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions

References

• Centers for Disease Control and Prevention. Bact Facts Interactive Beta v8.2. Active Bacterial Core surveillance (ABCs).
   Google Scholar
• Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, et al. Epidemiology of Invasive Streptococcus pneumoniae Infections in the United States, 1995-1998 Opportunities for Prevention in the Conjugate Vaccine Era. JAMA. 2001;285(13):1729–35. doi:10.1001/jama.285.13.1729.
   PubMed Web of Science ®Google Scholar
• Ahmed SS, Pondo T, Xing W, McGee L, Farley M, Schaffner W, Thomas A, Reingold A, Harrison L, Lynfield R, et al. Early Impact of 13-valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease among Adults with and without Underlying Medical Conditions-United States. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2019.
   Google Scholar
• Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, et al. Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine. N Engl J Med. 2003;348(18):1737–46. doi:10.1056/NEJMoa022823.
   PubMed Web of Science ®Google Scholar
• Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294(16):2043–51. doi:10.1001/jama.294.16.2043.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control & Prevention. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbidity and mortality weekly report 2012; 61:816–19.
   Google Scholar
• Cho BH, Stoecker C, Link-Gelles R, Moore MR Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine. 2013;31(50):6011–21. doi:10.1016/j.vaccine.2013.10.024.
   Google Scholar
• Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T.. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >/=65 Years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbidity and mortality weekly report 2014; 63:822–25.
   Google Scholar
• Stoecker C, Kobayashi M, Matanock A, Cho BH, Pilishvili T Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. Vaccine. 2019;38(7):1770–77. doi:10.1016/j.vaccine.2019.12.029.
   Google Scholar
• Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >/=65 Years: updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morbidity and mortality weekly report 2019; 68:1069–75.
   Google Scholar
• Palisade Corporation. @Risk 5.7. Newfield, NY2011.
   Google Scholar
• Centers for Disease Control and Prevention. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR 2010; 59:1102–06.
   Google Scholar
• Arias E, Xu J Unites States Life Tables, 2017. National Vital Statistics Reports, 2019.
   Google Scholar
• Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017; 135:e146–e603.
   Google Scholar
• Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, Volk ML. The Epidemiology of Cirrhosis in the United States: A Population-based Study. J Clin Gastroenterol. 2015;49(8):690–96. doi:10.1097/MCG.0000000000000208.
   PubMed Web of Science ®Google Scholar
• Rycroft CE, Heyes H, Lanza L, Becker K. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis. 2012;7:457–94. doi:10.2147/COPD.S32330.
   PubMed Web of Science ®Google Scholar
• Esser MB, Hedden SL, Kanny D, Brewer RD, Gfroerer JC, Naimi TS. Prevalence of Alcohol Dependence Among US Adult Drinkers, 2009–2011. Prev Chronic Dis. 2014;11:E206. doi:10.5888/pcd11.140329.
   PubMed Web of Science ®Google Scholar
• Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015;373(5):415–27. doi:10.1056/NEJMoa1500245.
   PubMed Web of Science ®Google Scholar
• Hayes BH, Haberling DL, Kennedy JL, Varma JK, Fry AM, Vora NM. Burden of Pneumonia-Associated Hospitalizations: united States, 2001-2014. Chest. 2018;153(2):427–37. doi:10.1016/j.chest.2017.09.041.
   PubMed Web of Science ®Google Scholar
• Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, Nakamatsu R, Pena S, Guinn BE, Furmanek SP, et al. Adults Hospitalized With Pneumonia in the United States: incidence, Epidemiology, and Mortality. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2017;65(11):1806–12. doi:10.1093/cid/cix647.
   PubMed Web of Science ®Google Scholar
• Weycker D, Farkouh RA, Strutton DR, Edelsberg J, Shea KM, Pelton SI. Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Serv Res. 2016;16(1):182. doi:10.1186/s12913-016-1432-4.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Jackson M, Yua O, Whitney CG, Bounds L, Bittner R, Zavitkovsky A, Jackson LA. Impact of the Introduction of Pneumococcal Conjugate Vaccine on Rates of Community Acquired Pneumonia in Children and Adults. Vaccine. 2008;26(38):4947–54. doi:10.1016/j.vaccine.2008.07.016.
   PubMed Web of Science ®Google Scholar
• Isturiz RE, Ramirez J, Self WH, Grijalva CG, Counselman FL, Volturo G, Ostrosky-Zeichner L, Peyrani P, Wunderink RG, Sherwin R, et al. Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. Vaccine. 2019;37(25):3352–61. doi:10.1016/j.vaccine.2019.04.087.
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AMM, Sanders EAM, Verheij TJM, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–25. doi:10.1056/NEJMoa1408544.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Almendares O, Nanduri S, Warnock R, Wu X, McKean S, Kelman J, Farley M, Schaffner W, Thomas A, et al. Case-Control Study to Evaluate Pneumococcal Vaccines Effectiveness against Invasive Pneumococcal Disease (IPD) Among U.S. Medicare Beneficiaries ≥65 Years Old. ISPPD Abstract 0682 2018.
   Google Scholar
• Suaya JA, Jiang Q, Scott DA, Gruber WC, Webber C, Schmoele-Thoma B, Hall-Murray CK, Jodar L, Isturiz RE. Post Hoc Analysis of the Efficacy of the 13-Valent Pneumococcal Conjugate Vaccine against Vaccine-type Community-acquired Pneumonia in at-risk Older Adults. Vaccine. 2018;36(11):1477–83. doi:10.1016/j.vaccine.2018.01.049.
   PubMed Web of Science ®Google Scholar
• Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C, Ho PL. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: systematic Review and Meta-Analysis. PloS One. 2017;12(1):e0169368. doi:10.1371/journal.pone.0169368.
   PubMed Web of Science ®Google Scholar
• Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus F-W, Chalmers JD. Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk – A Systematic Review and Meta-Analysis. PloS One. 2016;11(1):e0146338. doi:10.1371/journal.pone.0146338.
   PubMed Web of Science ®Google Scholar
• Tin Tin Htar M, Stuurman AL, Ferreira G, Alicino C, Bollaerts K, Paganino C, Reinert RR, Schmitt H-J, Trucchi C, Vestraeten T, et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PloS One. 2017;12(5):e0177985. doi:10.1371/journal.pone.0177985.
   PubMed Web of Science ®Google Scholar
• Hung M-C, Williams WW, Lu P-J, Woods LO, Koppaka R, Lidley MC Vaccination Coverage among Adults in the United States, National Health Interview Survey, 2017, 2018.
   Google Scholar
• Williams WW, Lu PJ, O’Halloran A, Kim DK, Grohskopf LA, Pilishvili T, Skoff TH, Nelson NP, Harpaz R, Markowitz LE, et al. Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014. Morbidity and mortality weekly report Surveillance summaries (Washington, DC: 2002) 2016; 65:1–36.
   Google Scholar
• Pilishvili T, Gierke R, Xing W, Farley M, Schaffner W, Thomas A, Reingold A, Harrison L, Lynfield R, McGuire S, et al. Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) use on Invasive Pneumococcal Disease (IPD) among Adults in the United States. ISPPD Abstract 0696. Melbourne, Australia., 2018.
   Google Scholar
• van der Linden M, Imöhl M, Perniciaro S, Melo-Cristino J. Limited indirect effects of an infant pneumococcal vaccination program in an aging population. PloS One. 2019;14(8):e0220453. doi:10.1371/journal.pone.0220453.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, Andrews NJ, Miller E, Ramsay ME. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–51. doi:10.1016/S1473-3099(18)30052-5.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Gierke R, Farley MM, Schaffner W, Thomas A, Reinert RR, Harrison LH, Holtzman C, McGuire G, Petit S, et al. Changes in Invasive Pneumococcal Disease (IPD) among Children Following 6 years of 13-valent Pneumococcal Conjugate Vaccine (PCV13) use in the United States. ISPPD Abstract 0643. Melbourne, Australia., 2018.
   Google Scholar
• Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America. 2013;57(7):952–62. doi:10.1093/cid/cit428.
   PubMed Web of Science ®Google Scholar
• Grant LR, O’Brien SE, Burbidge P, Haston M, Zancolli M, Cowell L, Johnson M, Weatherholtz RC, Reid R, Santosham M, et al. Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PloS One. 2013;8(9):e74906. doi:10.1371/journal.pone.0074906.
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. National Health Interview Survey.
   Google Scholar
• HCUP Databases. Healthcare Cost and Utilization Project (HCUP). Rockville(MD): Agency for Healthcare Research and Quality; 2014 [accessed 2019 Aug 29]. http://www.hcup-us.ahrq.gov/nisoverview.jsp
   Google Scholar
• Wyllie AL, Rümke LW, Arp K, Bosch A, Bruin JP, Rots NY, Wijmenga-Monsuur AJ, Sanders EAM, Trzciński K. Molecular surveillance on Streptococcus pneumoniae carriage in non-elderly adults; little evidence for pneumococcal circulation independent from the reservoir in children. Sci Rep. 2016;6(1):34888. doi:10.1038/srep34888.
   PubMed Web of Science ®Google Scholar
• Milucky J, Carvalho MDG, Rouphael N, Bennett NM, Talbot HK, Harrison LH, Farley MM, Walston J, Pimenta F, Lessa FC, et al. Streptococcus pneumoniae colonization after introduction of 13-valent pneumococcal conjugate vaccine for US adults 65 years of age and older, 2015–2016. Vaccine. 2019;37(8):1094–100. doi:10.1016/j.vaccine.2018.12.075.
   PubMed Web of Science ®Google Scholar
• Bruce MG, Singleton R, Bulkow L, Rudolph K, Zulz T, Gounder P, Hurlburt D, Bruden D, Hennessy T. Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska. Vaccine. 2015;33(38):4813–19. doi:10.1016/j.vaccine.2015.07.080.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlburt DA, Reasonover A, Hennessy T. Indirect Effect of Conjugate Vaccine on Adult Carriage of Streptococcus pneumoniae: an Explanation of Trends in Invasive Pneumococcal Disease. J Infect Dis. 2006;193(11):1487–94. doi:10.1086/503805.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–09. doi:10.1016/S1473-3099(14)71081-3.
   PubMed Web of Science ®Google Scholar
• Lewnard JA, Hanage WP. Making sense of differences in pneumococcal serotype replacement. Lancet Infect Dis. 2019;19(6):e213–e20. doi:10.1016/S1473-3099(18)30660-1.
   PubMed Web of Science ®Google Scholar
• Patterson S, Webber C, Patton M, Drews W, Huijts SM, Bolkenbaas M, Gruber WC, Scott DA, Bonten MJM. A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults). Trials Vaccinology. 2016;5:92–96. doi:10.1016/j.trivac.2016.04.004.
   Google Scholar
• van Werkhoven CH, Huijts SM, Bolkenbaas M, Grobbee DE, Bonten MJ. The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America. 2015;61(12):1835–38. doi:10.1093/cid/civ686.
   PubMed Web of Science ®Google Scholar
• Black CL, Williams WW, Warnock R, Pilishvili T, Kim D, Kelman JA Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged >/=65 Years. MMWR Morbidity and mortality weekly report 2017; 66:728–33.
   Google Scholar
• Finland M, Barnes MW. Changes in occurrence of capsular serotypes of Streptococcus pneumoniae at Boston City Hospital during selected years between 1935 and 1974. J Clin Microbiol. 1977;5:154–66.
   PubMed Web of Science ®Google Scholar
• Pfizer. Inc. internal sales data for PCV13. 2016.
   Google Scholar
• Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31–32):4203–14. doi:10.1016/j.vaccine.2004.05.003.
   PubMed Web of Science ®Google Scholar
• Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med. 2006;31(1):72–79. doi:10.1016/j.amepre.2006.03.008.
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. Consumer Price Index Archived News Releases.
   Google Scholar
• McLaughlin JM, Jiang Q, Gessner BD, Swerdlow DL, Sings HL, Isturiz RE, Jodar L. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis. Vaccine. 2019;37(43):6310–16. doi:10.1016/j.vaccine.2019.08.059.
   PubMed Web of Science ®Google Scholar
• van Deursen AMM, van Houten MA, Webber C, Patton M, Scott DA, Patterson S, Sidhu M, Drews W, Gruber WC, Emini EA, et al. Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2017; 65:787–95.
   Google Scholar
• Kim DS, Shin SH, Lee HJ, Hong YJ, Lee SY, Choi KM, Oh CE, Kim KH, Juergens C, Patterson S, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines. Pediatr Infect Dis J. 2013;32:266–73.
   PubMed Web of Science ®Google Scholar
• Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, Jansen KU, Love J, Gruber WC, Emini EA, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126(3):e493–505. doi:10.1542/peds.2009-3027.
   PubMed Web of Science ®Google Scholar
• Weckx LY, Thompson A, Berezin EN, de Faria SM, da Cunha CA, Pride M, Patterson S, Gruber WC, Emini EA, Scott DA, et al. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil. Vaccine. 2012;30(52):7566–72. doi:10.1016/j.vaccine.2012.10.040.
   PubMed Web of Science ®Google Scholar
• Kieninger DM, Kueper K, Steul K, Juergens C, Ahlers N, Baker S, Jansen KU, Devlin C, Gruber WC, Emini EA, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28(25):4192–203. doi:10.1016/j.vaccine.2010.04.008.
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, Slack M, Ladhani SN, Miller E, Goldblatt D, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–46. doi:10.1016/S1473-3099(14)70822-9.
   PubMed Web of Science ®Google Scholar
• Stoecker C, Kim L, Gierke R, Pilishvili T. Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States. J Gen Intern Med. 2016;31(8):901–08. doi:10.1007/s11606-016-3651-0.
   PubMed Web of Science ®Google Scholar
• Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK, Smith KJ. Pneumococcal Vaccination in Adults Aged ≥65 Years: cost-Effectiveness and Health Impact in U.S. Populations. American Journal of Preventive Medicine. 2020;58(4):487–95. doi:10.1016/j.amepre.2019.10.022.
   PubMed Web of Science ®Google Scholar
• Merck & Co. Inc. Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants. May 8, 2019.
   Google Scholar
• Pfizer Inc. Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults Aged 18 Years or Older. March 18, 2020.
   Google Scholar